Zentalis Pharmaceuticals (ZNTL) Non-Current Assets (2019 - 2026)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Non-Current Assets of $35.0 million for Q1 2026, down 15.0% year-over-year from $41.1 million in Q1 2025, and down 2.25% quarter-over-quarter from $35.8 million in Q4 2025.
Zentalis Pharmaceuticals (ZNTL) Non-Current Assets (2019 - 2026) Analysis & Trends
Zentalis Pharmaceuticals' Non-Current Assets history runs 8 years deep, the most recent figure standing at $35.0 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 15.0% year-over-year to $35.0 million; the TTM figure through Mar 2026 stood at $149.8 million (down 20.26% YoY), while the FY2025 annual figure was $35.8 million, down 19.19% from the prior year.
- Non-Current Assets for Q1 2026 stood at $35.0 million, down from $35.8 million in the prior quarter.
- The five-year high for Non-Current Assets was $104.4 million in Q1 2022, with the low at $35.0 million in Q1 2026.
- The 5-year median for Non-Current Assets is $53.7 million (2024), against an average of $60.5 million.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets soared 374.54% in 2022, then sank 42.62% in 2023.
- Zentalis Pharmaceuticals' Non-Current Assets stood at $87.4 million in 2022, then sank by 37.09% to $55.0 million in 2023, then decreased by 19.46% to $44.3 million in 2024, then decreased by 19.19% to $35.8 million in 2025, then slipped by 2.25% to $35.0 million in 2026.
- Business Quant data shows ZNTL's Non-Current Assets at $35.0 million in Q1 2026, $35.8 million in Q4 2025, and $38.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Zentalis Pharmaceuticals | 255.14 Mn | 255.14 Mn | - | 34.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.05 Mn |
| Mar 31, 2026 | 34.97 Mn |
| Dec 31, 2025 | 35.78 Mn |
| Sep 30, 2025 | 38.95 Mn |
| Jun 30, 2025 | 40.11 Mn |
| Mar 31, 2025 | 41.14 Mn |
| Dec 31, 2024 | 44.27 Mn |
| Sep 30, 2024 | 50.39 Mn |
| Jun 30, 2024 | 52.06 Mn |
| Mar 31, 2024 | 53.67 Mn |
| Dec 31, 2023 | 54.97 Mn |
| Sep 30, 2023 | 57.45 Mn |
| Jun 30, 2023 | 57.52 Mn |
| Mar 31, 2023 | 79.12 Mn |
| Dec 31, 2022 | 87.38 Mn |
| Sep 30, 2022 | 95.30 Mn |
| Jun 30, 2022 | 100.23 Mn |
| Mar 31, 2022 | 104.40 Mn |
| Dec 31, 2021 | 103.74 Mn |
| Sep 30, 2021 | 57.52 Mn |